Emergent Travel Health
48 articles about Emergent Travel Health
-
PaxVax, Inc. Announces Positive Interim Results For Phase 3 Cholera Challenge Study; Clinical Trial Program To Proceed As Planned
1/9/2014
-
PaxVax, Inc. Secures $22 Million Series B Financing
12/4/2013
-
PaxVax, Inc. Initiates Phase 3 Clinical Trial Challenge Studies for Single-Dose Oral Cholera Vaccine
9/6/2013
-
PaxVax, Inc. Announces Positive Results for Oral Ad4 Vaccine Technology
1/31/2013
-
PaxVax, Inc. Presents Phase 1 Clinical Trial Data for Single-Dose Cholera Vaccine
11/14/2012
-
FDA Accepts PaxVax, Inc.’s IND for Single-Dose Oral Cholera Vaccine
3/19/2012
-
PaxVax, Inc. Expands Executive Management Team
2/9/2012
-
San Diego's PaxVax, Inc. Developing Oral Tablet Vaccine, Looks to Raise More Cash With Support of Seattle’s Ignition Capital
11/9/2009